Please login to the form below

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Lilly partners with Merus on development of bispecific antibodies for cancer

Eli Lilly has entered a research collaboration agreement with Dutch biotech Merus to develop CD3-engaging bispecific antibodies for the treatment of cancer. ... products. "CD3-engaging bispecific antibodies are rapidly becoming one of the most

Latest news

Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

Sanofi and Regeneron are also working on bispecific antibody immunotherapies, including two lead candidate targeting BCMA/CD3 and MUC/CD3, respectively.
Regeneron reveals first data for bispecific antibody in multiple myeloma

The antibody targets BCMA, a protein that is typically over-expressed on multiple myeloma cells, by binding to it and the CD3 receptor on T-cells, bringing them together and activating ... CD3 targeting bispecific antibody.
Provention Bio wins PRIME designation for type 1 diabetes prevention drug

Teplizumab works by binding to the pro-inflammatory T cell co-receptor CD3, which in turn prevents them from activating the T cells that attack and kill the pancreas’ beta cells.
Tiziana joins type 1 diabetes prevention field

Teplizumab is a mouse derived anti-CD3 mAb, and is administered intravenously. ... Now Tiziana is looking to rival Provention with the development of its own anti-CD3 mAB foralumab, which it says is the only entirely human anti-CD3 mAb.
Roche’s Polivy gets FDA okay for lymphoma chemo-immunotherapy

Roche is also looking at combining Polivy with its CD20/CD3 bispecific antibody mosunetuzumab in DLBCL and follicular lymphoma, and moving the ADC into earlier lines of therapy.

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches

The reason the molecule is called ‘bispecific’ is that it is engineered from not one but two antibodies: one is designed to engage with CD3, which is found on T cells;
Taking a lean and careful approach

Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Deal Watch June 2016

Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
Pharma deals during December 2014

platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Account Management: Competitive Salary Offered

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

PMHub

Add my company

TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

How a design mindset can lead to better medical outcomes: By adopting a design philosophy, healthcare companies can develop communications that allow healthcare professionals (HCPs) to better meet the needs of their patients. Imaginatively designed content combined with patient insights...
How does the government plan to reshape the NHS?: Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human: In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...